{"transactions":[{"id":3060275,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":3644624,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":487438},"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3060274,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":8753350,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1314165},"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3060273,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":12500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1671771},"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3060272,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"purchase","acquired":true,"shares":133333,"price":15,"value":1999995.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":3606707,"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3060271,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":1,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":2,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-12T21:04:57.000Z","date":"2020-08-11","kind":"exercise","acquired":true,"shares":3473374,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":3473374,"source":{"system":"sec-edgar","filing":"0000899243-20-022200","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924320022200/doc4.xml","form_type":"4"}},{"id":3124067,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2020-06-03T20:20:13.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":400000,"price":1.6074,"value":642960.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":1226514,"source":{"system":"sec-edgar","filing":"0001104659-20-069570","document":"tm2021737d1_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000110465920069570/tm2021737d1_form4.xml","form_type":"4"}},{"id":3124066,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2020-06-03T20:20:13.000Z","date":"2020-06-01","kind":"sale","acquired":false,"shares":100000,"price":1.6912,"value":169120.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any."}],"balance_after":1626514,"source":{"system":"sec-edgar","filing":"0001104659-20-069570","document":"tm2021737d1_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000110465920069570/tm2021737d1_form4.xml","form_type":"4"}},{"id":3304098,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.500% Exchangeable Senior Subordinated Note due 2025","published_at":"2020-01-23T19:25:59.000Z","date":"2020-01-21","kind":"grant","acquired":true,"price":1750000,"reported_value":1750000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Exchangeable Note is held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any. Dr. Anand Mehra, a reporting person on the Fund's prior Section 16 filings with respect to the Company, is no longer a managing member of the GP, and accordingly, is not a reporting person on this Form 4."}],"derivative":{"expiration_date":"2025-01-31","underlying":"Ordinary Shares","underlying_shares":1750000},"source":{"system":"sec-edgar","filing":"0001104659-20-006401","document":"tm205635-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000110465920006401/tm205635-1_4.xml","form_type":"4"}},{"id":3365956,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-19T21:47:49.000Z","date":"2019-11-15","kind":"purchase","acquired":true,"shares":150000,"price":36.75,"value":5512500.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2671856,"source":{"system":"sec-edgar","filing":"0001104659-19-065582","document":"tm1923401-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000110465919065582/tm1923401-1_4.xml","form_type":"4"}},{"id":3374518,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":2709659,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":535869},"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3374517,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":9090909,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1797843},"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3374516,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"purchase","acquired":true,"shares":750000,"price":12,"value":9000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":3083712,"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3374515,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"exercise","acquired":true,"shares":2333712,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":2333712,"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3526046,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":3773585,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":469713},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526045,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":7301000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":908785},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526044,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":3732500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":464599},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526043,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":2239500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":278759},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526042,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":400000,"price":15,"value":6000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2521856,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526041,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":469713,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2121856,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526040,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":908785,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1652143,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526039,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":464599,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":743358,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526038,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":278759,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":278759,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3801417,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":9502249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458425},"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801416,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7446904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359267},"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801415,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":337724,"price":15,"value":5065860.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":1180178,"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801414,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":458425,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":842454,"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801413,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":359267,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":359267,"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3914142,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":229660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":229660},"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914141,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":275446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":275446},"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914140,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":721408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":721408},"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914139,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"purchase","acquired":true,"shares":500000,"price":13,"value":6500000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":1726514,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914138,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":229660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":1226514,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914137,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":275446,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":996854,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914136,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":721408,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":721408,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}}]}